Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReVeRA-301 phase 3 trial of etripamil nasal spray for atrial fibrillation with rapid ventricular rate
2024-516251-40-01Phase 3Authorised
- Sponsor
- Milestone Pharmaceuticals
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Etripamil nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Maximum reduction in ventricular rate within 30 minutes. Planned start Sep 2026; status: authorised.
02
Drugs
etripamil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-516251-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516251-40-01.